2025 Annual Report of Independent Director
Dear shareholders and shareholder representatives:
As an independent director of Guangdong Meilian New Materials Co., Ltd. (hereinafter referred to as "the Company"), I have strictly adhered to the provisions of the Company Law of the People's Republic of China, the Management Measures for Independent Directors of Listed Companies, and other relevant laws and regulations, as well as the Company’s Articles of Association and the Independent Director Work System. I have diligently fulfilled my duties, actively attended all board meetings and shareholder meetings, carefully reviewed various proposals, and provided independent, objective, and professional opinions to effectively safeguard the interests of the Company and its shareholders. I hereby report on my performance of independent director duties during the 2025 term as follows:
1. Basic Information
Chen Xiaowei, male, born in 1966, Chinese nationality, without permanent residency abroad. Bachelor’s degree in Electrical Engineering from South China University of Technology, Master’s degree in Business Administration from South China University of Technology, Senior Engineer in Electrical Engineering, International Registered Internal Auditor, and Economist. Currently serving as an entrepreneur mentor at the MBA Education Center of Shantou University Business School. Since February 2017, I have been a director, board secretary, and deputy general manager of Guangdong Runke Bioengineering Co., Ltd.; since February 2024, an independent director of Guangdong Taienkang Pharmaceutical Co., Ltd.; since December 2024, an independent director of Guangzhou Zhiguang Electric Co., Ltd.; and since January 2025, an independent director of the Company. My qualifications meet the independence requirements stipulated in Article 6 of the Management Measures for Independent Directors of Listed Companies, and there are no circumstances affecting my independence.
2. Annual Performance Overview
During the reporting period, I actively participated in all board meetings and shareholder meetings that I was required to attend, diligently reviewing meeting proposals and related materials, actively engaging in discussions, and providing reasonable suggestions, thereby contributing positively to the board's correct and scientific decision-making. In 2025, the convening of the Company’s board and shareholder meetings complied with legal procedures, and all significant operational decisions and other major matters followed the relevant approval processes. My attendance at meetings is as follows:
(1) Attendance at Shareholder Meetings
During the reporting period, the Company held 6 shareholder meetings, and I was required to attend 5 of them, all of which I attended in person or via communication.
(2) Attendance at Board Meetings
During the reporting period, the Company held 10 board meetings, and I was required to attend 9 of them, all of which I attended in person or via communication. The specific situation is as follows:
| Name | Required Attendance | In-Person Attendance | Proxy Attendance | Absences | Consecutive Absences |
|---|---|---|---|---|---|
| Chen Xiaowei | 9 | 9 | 0 | 0 | No |
During the reporting period, I voted in favor of all proposals submitted at each board meeting after careful review, with no objections or abstentions, and did not raise any dissenting opinions on any matters of the Company.